| Trial ID: | L1579 |
| Source ID: | NCT04654507
|
| Associated Drug: |
Dexamethasone Oral
|
| Title: |
Efficacy of Corticosteroids in Reducing Renal Scarring in Acute Pyelonephritis in Children
|
| Acronym: |
|
| Status: |
RECRUITING
|
| Study Results: |
NO
|
| Results: |
|
| Conditions: |
Urinary Tract Infections in Children|Dexamethasone|Kidney Scarring|Acute Pyelonephritis|Hypertension in Children|Chronic Renal Failure|UTI
|
| Interventions: |
DRUG: Dexamethasone Oral|DRUG: Placebo
|
| Outcome Measures: |
Primary: Renal scarring comparatively with patients those don't take the medicine, Division of Children With Renal Scarring at the Outcome of (DMSA) Renal Scan \[ Time Frame: The outcome DMSA scan will be 6 months from enrollment.\] Renal scarring is defined as decreased uptake of tracer with or without loss of contours. Three radiologists independently will review all renal DMSA scans for scarring . Diagnosis of presence or absence of renal scarring for a kidney , should be endorsed by the majority of readers (2/3). The child will be determined to have renal scarring if either kidney or both kidneys have scarring by the majority of readers., 6 months |
|
| Sponsor/Collaborators: |
Sponsor: Hamad Medical Corporation
|
| Gender: |
ALL
|
| Age: |
CHILD
|
| Phases: |
PHASE3
|
| Enrollment: |
120
|
| Study Type: |
INTERVENTIONAL
|
| Study Designs: |
Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: QUADRUPLE (PARTICIPANT, CARE_PROVIDER, INVESTIGATOR, OUTCOMES_ASSESSOR)|Primary Purpose: PREVENTION
|
| Start Date: |
2021-03-03
|
| Completion Date: |
2024-12
|
| Results First Posted: |
|
| Last Update Posted: |
2023-07-25
|
| Locations: |
Hamad Medical Corporation, Doha, 3050, Qatar
|
| URL: |
https://clinicaltrials.gov/show/NCT04654507
|
